Skip to main content
. Author manuscript; available in PMC: 2021 Jun 3.
Published in final edited form as: Pharmacogenomics J. 2020 Jun 5;20(6):831–839. doi: 10.1038/s41397-020-0171-4

Table 2B:

Additional analyses of CYP2C9 genotypes and sulfonylurea-related hypoglycemia in European American patients

Type of Analysis Minimally adjusted Fully adjusted
*1/*11 *1/*2, *1/*3, *2/*2, *2/*3, or *3/*31 OR (95% CI) p-value *1/*11 *1/*2, *1/*3, *2/*2, *2/*3, or *3/*31 OR (95% CI) p-value
By Severity of Hypoglycemia
 Asymptomatic 142/769(18.5) 97/509 (19.1) 1.05 (0.79, 1.40) 0.74 136/731 (18.6) 95/495 (19.2) 1.02 (0.78, 1.37) 0.90
 Probable 47/674 (7.0) 21/433 (4.8) 0.67 (0.40, 1.14) 0.67 46/641 (7.2) 21/421 (5.0) 0.67 (0.40, 1.15) 0.15
 Documented 30/657 (4.6) 13/425 (3.1) 0.66 (0.34, 1.28) 0.22 30/625 (4.8) 13/413 (3.1) 0.64 (0.33, 1.25) 0.20
 Severe 5/632 (0.8) 1/413 (0.2) 0.30 (0.04, 2.63) 0.28 5/300 (0.8) 1/401 (0.2) 0.29 (0.03, 2.59) 0.27
Stratified by type of sulfonylurea
 Glimepiride 77/297 (25.9) 40/186 (21.5) 0.77 (0.50, 1.20) 0.25 75/281 (26.7) 40/180 (22.2) 0.78 (0.50, 1.22) 0.27
 Glyburide 61/278 (21.9) 40/178 (22.5) 1.04 (0.66, 1.63) 0.88 61/276 (22.1) 40/176 (22.7) 1.05 (0.66, 1.66) 0.84
 Glipizide 86/276 (31.2) 52/180(28.9) 0.89 (0.59, 1.35) 0.59 81/255 (31.8) 50/174 (28.7) 0.84 (0.55, 1.30) 0.44
Stratified by POR genotype:
 *1/*1 121/443 (27.3) 70/291 (24.1) 0.83 (0.59, 1.17) 0.30 118/428 (27.6) 69/280 (24.6) 0.85 (0.60, 1.21) 0.37
 *1/*28 91/346 (26.3) 47/217 (21.7) 0.77 (0.52, 1.15) 0.21 88/325 (27.1) 46/215 (21.4) 0.72 (0.47, 1.09) 0.12
 *28/*28 12/62 (19.4) 15/36 (41.7) 3.01 (1.20, 7.53) 0.019 11/59 (18.6) 15/35 (42.9) 4.36 (1.48, 12.80) 0.007
Type of Analysis Minimally adjusted Fully adjusted
*1/*11 *2/*2, *2/*3, or *3/*3a OR (95% CI) p-value *1/*11 *2/*2, *2/*3, or *3/*31 OR (95% CI) p-value
Wild type vs compound heterozygous or homozygous 224/851 (26.3) 18/59 (30.5) 1.22 (0.68, 2.16) 0.51 217/812 (26.7) 18/59 (30.5) 1.11 (0.62 – 1.98) 0.73

All logistic regression analyses were performed assuming a dominant model. OR (95%CI): odds ratio (95% confidence interval); P: P-value

Minimally adjusted model: include sex and age as covariates.

Fully adjusted model: include age, sex, type of sulfonylurea, dose of sulfonylurea, BMI, creatinine, and concomitant use of other oral antidiabetics

1

The cells represent the number of cases with the genotype / number of cases and controls with the genotype per category. The category is defined by the row variable.